Vor Biopharma, Inc. (VOR) PT Lowered to $22 at Baird
- Wall Street ends down as megacaps give back gains
- Current S&P 500 valuation is not leaving 'any margin for error' - JPMorgan
- Dow Jones, Nasdaq, S&P 500 weekly preview: Can this rally hold?
- Stocks retreat after rally with jobs data eyed, yields climb
- Alaska Air (ALK) drops 9% on $1.9 billion deal to buy Hawaiian (HA)
Baird analyst Jack Allen lowered the price target on Vor Biopharma, Inc. (NASDAQ: VOR) to $22.00 (from $38.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Mizuho upgrades GM to Buy following cost cuts and a production reset
- Goldman Sachs Downgrades INWIT (INW:IM) to Neutral
- Coca-Cola Europacific Partners (CCEP:NA) (CCEP) PT Raised to EUR64 at Goldman Sachs
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!